Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction

Expert Opinion on Investigational Drugs

Volumn 12, Issue 3, 2003, Pages 501-507

  Salam, Amar M ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Acute myocardial infarction; Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; TRANDOLAPRIL; VALSARTAN; ZOFENOPRIL;

ACUTE HEART INFARCTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPOTENSION; LONG TERM CARE; MORTALITY; PATIENT SELECTION; PROGNOSIS; REVIEW; SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HUMANS; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0037341740     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.3.501     Document Type: Review

References (29)

1. BRUNNER HR, LARAGH JH, BAER L et al.: Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. (1972) 286:441-449.
2. ONDETTI MA, RUBIN B, CUSHMAN DW: Design of specific angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science (1977) 196:441-444.
3. URATA H, HEALY B, STEWART RW, BUMPUS FM, HUSAIN A: Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. (1990) 66:883-890.
4. ARDAILLOU R: Angiotensin II receptors. J. Am. Soc. Nephrol. (1999) 10:S30-S39.
5. OLIVERIO MI, COFFMAN TM: Angiotensin-II-receptors: new targets for antihypertensive therapy. Clin. Cardiol. (1997) 20:3-6.
6. NIO Y, MATSUBARA H, MURASAWA S, KANASAKI M, INADA M: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin. Invest. (1995) 95:46-54.
7. TEIGER E, THAN VD, RICHARD L et al.: Apoptosis in pressure overload induced heart hypertrophy in the rat. J Clin. Invest. (1996) 97:2891-2897.
8. STOLL M, STECKELINGS UM, PAUL M et al.: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. (1995) 95:651-657.
9. URATA H, KINOSHITA A, MISONO KS, BUMPUS FM, HUSAIN A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. (1990) 265:22348-22357.
10. GAINER JV, MORROW JD, LOVELAND A, KING DJ, BROWN NJ: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. (1998) 339:1285-1292.
11. SHARPE N, MURPHY J, SMITH H, HANNAN S: Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet (1988) 1(8580):255-259.
12. PFEFFER MA, LAMAS GA, VAUGHAN DE, PARISI AF, BRAUNWALD E: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N. Engl. J. Med. (1988) 319:80-86.
13. PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. (1992) 327:669-677.
14. THE ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:821-828.
15. HALL AS, MURRAY GD, BALL SG: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet (1997) 349:1493-1497.
16. KOBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. (1995) 333:1670-1676.
17. AMBROSIONI E, BORGHI C, MAGNANI B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. (1995) 332:80-85.
18. BORGHI C, AMBROSIONI E: Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am. Heart J. (2003) 145:80-87.
19. SWEDBERG K, HELD P, KJEKSHUS J, RASMUSSEN K, RYDEN L, WEDEL H: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. (1992) 327:678-684.
20. GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL'INFARTO MIOCARDICO: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet (1994) 343:1115-1122.
21. AVANZINI F, FERRARIO G, SANTORO L et al.: Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database. Am. Heart J. (2002) 144:1018-25.
22. ISIS-4 COLLABORATIVE GROUP: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet (1995) 345:669-685.
23. CHINESE CARDIAC STUDY (CCS-1) COLLABORATIVE GROUP: Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chin. Med. J. (Engl) (1997) 110:834-838.
24. PFEFFER MA, GREAVES SC, ARNOLD JM et al.: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation (1997) 95:2643-2651.
25. BORGHI C, MARINO P, ZARDINI P, MAGNANI B, COLLATINA S, AMBROSIONI E: Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS). Am. J. Hypertens. (1997) 10:247S-254S.
26. YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
27. DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet (2002) 360:752-760.
28. PFEFFER MA, MCMURRAY J, LEIZOROVICZ A et al. for the VALIANT investigators: Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am. Heart J. (2000) 140:727-750.
29. PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582-1587.